cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5281/zenodo.18619106
title: Formula 1 Qualifying and Race Results: Ground Effect Era (2022–2025)

description: This dataset provides a structured record of qualifying and race classification results from the Formula 1 Ground Effect Era (2022–2025).

Beginning in 2022, Formula 1 introduced a new aerodynamic framework centred on ground-effect floor designs aimed at reducing wake turbulence and enabling closer on-track racing. The regulations simplified upper-body aerodynamic surfaces, eliminated bargeboards, redesigned front and rear wings, and placed greater emphasis on underfloor venturi tunnels for downforce generation, while maintaining the 1.6-litre turbo-hybrid power unit architecture used in the preceding era.

During this period, sprint weekend formats were introduced and subsequently revised, altering the structure of selected race weekends and the determination of starting grids.

The competitive landscape during this era was more distributed than in the preceding period. Red Bull Racing won the Constructors’ Championships in 2022 and 2023, while McLaren secured the Constructors’ titles in 2024 and 2025. Max Verstappen won the Drivers’ Championship in 2022, 2023, and 2024, with Lando Norris winning the 2025 Drivers’ Championship.

Each entry represents a driver–event classification and includes:



Championship season and round number,

Official Grand Prix name,

Consistent driver identifier and driver name,

Constructor (team) at the event,

Final classified qualifying position,

Official race grid position,

Final classified race finishing position,

Net position change during the race (finish position minus grid position),

Qualifying session times (Q1, Q2, Q3 where applicable), and

Classification status (e.g. Finished, DNF, DSQ).


The dataset has been harmonised to ensure consistent driver identifiers, constructor naming, and alignment across varying weekend formats, including sprint-affected race grids.

Typical applications include comparative analysis across regulatory eras, modelling of positional movement and race outcomes, and use in teaching contexts involving data science and sports analytics.

The datasets and accompanying documentation are provided as CSV and Markdown files.
DOI: 10.6084/m9.figshare.31323895
title: Metadata to Chem Eng J 522 (2025) 167518

description: This repository contains the raw experimental datasets associated with the publication in Chem Eng J 522 (2025) 167518. The study was funded by the National Science Centre (NCN), Poland, under grant no. 2023/51/D/ST8/00206.
DOI: 10.6084/m9.figshare.31323895.v1
title: Metadata to Chem Eng J 522 (2025) 167518

description: This repository contains the raw experimental datasets associated with the publication in Chem Eng J 522 (2025) 167518. The study was funded by the National Science Centre (NCN), Poland, under grant no. 2023/51/D/ST8/00206.
DOI: 10.15468/dl.pvx8y2
title: Occurrence Download

description: A dataset containing 3139 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Magnolia champaca",
 "HasCoordinate is true",
 "OccurrenceStatus is Present",
 {
 "not" : {
 "BasisOfRecord" : [
 "is Fossil"
 ]
 }
 }
 ]
}

 The dataset includes 3139 records from 140 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0011189-260208012135463/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.34740/kaggle/dsv/14797960
title: DVT Classification for Thrombus and  Non-Thrombus
DOI: 10.5281/zenodo.18619290
title: Scotland's changing flora: A summary of the results of Plant Atlas 2020 - expert attribution of drivers to trends

description: Expert attribution of drivers to trends in vascular plants in Scotland over the long and short-term based on the results of Plant Atlas 2020. Attributions are included for the the 200 species that increased or decreased the most over both the long and short-term.
DOI: 10.5281/zenodo.18495546
title: Friction Coefficient of Bicycle Trailer Tyres at Different Inflation Pressures and on Different Surfaces

description: This repository contains the load cell data collected over an experimental campaign to measure the static friction coefficient of bicycle tyres over different surfaces, as a function of the inflation pressure.
DOI: 10.5281/zenodo.18495547
title: Friction Coefficient of Bicycle Trailer Tyres at Different Inflation Pressures and on Different Surfaces

description: This repository contains the load cell data collected over an experimental campaign to measure the static friction coefficient of bicycle tyres over different surfaces, as a function of the inflation pressure.
DOI: 10.15468/dl.tp2cuz
title: Occurrence Download

description: A dataset containing 1 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Hypancistrus margaritatus",
 "DecimalLatitude is not null",
 "DecimalLongitude is not null"
 ]
}

 The dataset includes 1 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0011188-260208012135463/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.18494893
title: Viscoelastic properties of bicycle tyres - Dynamic stiffness & damping

description: This repository contains the accelerometer and laser triangulation displacement sensor data collected over an experimental campaign to measure the radial stiffness and damping of bicycle tyres subjected to impact loading. For the tests, we employed a novel test-rig specifically designed to simulate and measure the tyre dynamic properties following a drop (or an impact).
DOI: 10.5281/zenodo.18494892
title: Viscoelastic properties of bicycle tyres - Dynamic stiffness & damping

description: This repository contains the accelerometer and laser triangulation displacement sensor data collected over an experimental campaign to measure the radial stiffness and damping of bicycle tyres subjected to impact loading. For the tests, we employed a novel test-rig specifically designed to simulate and measure the tyre dynamic properties following a drop (or an impact).
DOI: 10.15468/dl.jkgka3
title: Occurrence Download

description: A dataset containing 1341 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Cyclanthus bipartitus",
 "HasCoordinate is true",
 "BasisOfRecord is one of (Specimen)"
 ]
}

 The dataset includes 1341 records from 79 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0011190-260208012135463/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.31323907
title: Supplementary Material for: Cardiometabolic Syndromes and Associated Cardiovascular Risks: A Narrative Review

description: Cardiovascular risk (CVR) represents a major global health challenge due to its strong association with metabolic and endocrine disorders. Conditions such as metabolic syndrome (MetS), hypertriglyceridemic waist (HTGW), metabolic dysfunction-associated steatotic liver disease (MASLD), cardiorenometabolic syndrome (CKM), and polycystic ovary syndrome (PCOS) share overlapping but distinct clinical and pathophysiological features. Common mechanisms include insulin resistance, adipose tissue dysfunction, low-grade inflammation, and lipid abnormalities, which collectively contribute to vascular injury and cardiometabolic progression. MetS reflects central obesity often accompanied by hypertension and dyslipidaemia, while HTGW identifies visceral adiposity and metabolic imbalance. MASLD, formerly known as NAFLD, is now recognised as an independent predictor of cardiovascular morbidity and mortality. CKM encompasses the continuum of metabolic, renal, and cardiovascular dysfunction with additive effects on global risk. PCOS, prevalent among women of reproductive age, involves metabolic and hormonal disturbances that promote endothelial dysfunction and atherogenesis. This review synthesises current evidence linking these entities within a unified cardiometabolic framework and highlights the need for integrated risk stratification. Precision medicine approaches combining clinical, biochemical, and imaging biomarkers may allow early identification of subclinical phenotypes, enabling timely and targeted interventions to modify disease trajectories and reduce long-term cardiovascular burden.
DOI: 10.6084/m9.figshare.31323907.v1
title: Supplementary Material for: Cardiometabolic Syndromes and Associated Cardiovascular Risks: A Narrative Review

description: Cardiovascular risk (CVR) represents a major global health challenge due to its strong association with metabolic and endocrine disorders. Conditions such as metabolic syndrome (MetS), hypertriglyceridemic waist (HTGW), metabolic dysfunction-associated steatotic liver disease (MASLD), cardiorenometabolic syndrome (CKM), and polycystic ovary syndrome (PCOS) share overlapping but distinct clinical and pathophysiological features. Common mechanisms include insulin resistance, adipose tissue dysfunction, low-grade inflammation, and lipid abnormalities, which collectively contribute to vascular injury and cardiometabolic progression. MetS reflects central obesity often accompanied by hypertension and dyslipidaemia, while HTGW identifies visceral adiposity and metabolic imbalance. MASLD, formerly known as NAFLD, is now recognised as an independent predictor of cardiovascular morbidity and mortality. CKM encompasses the continuum of metabolic, renal, and cardiovascular dysfunction with additive effects on global risk. PCOS, prevalent among women of reproductive age, involves metabolic and hormonal disturbances that promote endothelial dysfunction and atherogenesis. This review synthesises current evidence linking these entities within a unified cardiometabolic framework and highlights the need for integrated risk stratification. Precision medicine approaches combining clinical, biochemical, and imaging biomarkers may allow early identification of subclinical phenotypes, enabling timely and targeted interventions to modify disease trajectories and reduce long-term cardiovascular burden.
DOI: 10.6084/m9.figshare.31323910
title: Supplementary Material for: Chronic Myeloid Leukemia Transforming into Acute Lymphoblastic Leukemia in a Patient with Gaucher Disease: A Case Report and Literature Review

description: Introduction
Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder characterized by glucocerebrosidase deficiency and accumulation of glucosylceramide within macrophages. Although GD is associated with an increased risk of hematologic malignancies—particularly multiple myeloma—the coexistence of GD with chronic myeloid leukemia (CML) is exceedingly rare. Even more unusual is leukemic transformation of CML into acute lymphoblastic leukemia (ALL) in the setting of GD, a phenomenon not previously documented in the literature. Understanding such associations is essential, as chronic inflammation, altered macrophage biology, and immune dysregulation in GD may influence oncogenesis and disease evolution.
Case Presentation
We report a 54-year-old man with GD type 1, splenectomized in childhood and on long-term enzyme replacement therapy, who was diagnosed with Philadelphia chromosome–positive CML following evaluation for leukocytosis. Despite an initial optimal response to imatinib, his molecular response plateaued, and one year later he developed relapse with B-lymphoblastic transformation. Flow cytometry and molecular studies confirmed B-ALL. The patient was treated with the EWALL protocol combined with dasatinib, achieving complete remission and MRD negativity. During consolidation, he developed severe neutropenic fever, fungal pneumonia, and massive pleural effusion attributed to dasatinib. Therapy was switched to bosutinib with successful control of effusion and sustained molecular remission for 27 months.
Conclusion
This is the first reported case of B-ALL transformation arising from CML in a patient with underlying GD. The case highlights that malignancies in the context of GD may follow an accelerated or atypical course. Close monitoring for disease evolution and careful management of TKI-related toxicities are critical in this unique clinical setting.
DOI: 10.6084/m9.figshare.31323910.v1
title: Supplementary Material for: Chronic Myeloid Leukemia Transforming into Acute Lymphoblastic Leukemia in a Patient with Gaucher Disease: A Case Report and Literature Review

description: Introduction
Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder characterized by glucocerebrosidase deficiency and accumulation of glucosylceramide within macrophages. Although GD is associated with an increased risk of hematologic malignancies—particularly multiple myeloma—the coexistence of GD with chronic myeloid leukemia (CML) is exceedingly rare. Even more unusual is leukemic transformation of CML into acute lymphoblastic leukemia (ALL) in the setting of GD, a phenomenon not previously documented in the literature. Understanding such associations is essential, as chronic inflammation, altered macrophage biology, and immune dysregulation in GD may influence oncogenesis and disease evolution.
Case Presentation
We report a 54-year-old man with GD type 1, splenectomized in childhood and on long-term enzyme replacement therapy, who was diagnosed with Philadelphia chromosome–positive CML following evaluation for leukocytosis. Despite an initial optimal response to imatinib, his molecular response plateaued, and one year later he developed relapse with B-lymphoblastic transformation. Flow cytometry and molecular studies confirmed B-ALL. The patient was treated with the EWALL protocol combined with dasatinib, achieving complete remission and MRD negativity. During consolidation, he developed severe neutropenic fever, fungal pneumonia, and massive pleural effusion attributed to dasatinib. Therapy was switched to bosutinib with successful control of effusion and sustained molecular remission for 27 months.
Conclusion
This is the first reported case of B-ALL transformation arising from CML in a patient with underlying GD. The case highlights that malignancies in the context of GD may follow an accelerated or atypical course. Close monitoring for disease evolution and careful management of TKI-related toxicities are critical in this unique clinical setting.
DOI: 10.6084/m9.figshare.31323913
title: Supplementary Material for: Comparison of HBeAg clearance rates between tenofovir alafenamide and entecavir in treatment-naive HBeAg positive chronic hepatitis B patients over 48 to 96 weeks: A retrospective cohort study

description: Objectives: This retrospective cohort study aimed to compare HBeAg clearance rates at 48 and 96 weeks in treatment-naïve, HBeAg-positive CHB patients receiving TAF versus ETV therapy 
Patients and Methods: Of 425 initially screened HBeAg-positive CHB patients, 251 were included in the 48-week analysis (ETV: 119; TAF: 132) and 101 in the 96-week analysis (ETV: 41; TAF: 60).PSM was used to balance baseline characteristics. Multivariate cox regression identified factors associated with HBeAg clearance. 
Results: At 48 weeks, a 1:1 PSM created balanced groups of 77 patients each for the 48-week comparison. the HBeAg clearance rate was significantly higher in the TAF group than in the ETV group: 22.1% versus 6.5% (χ²= 7.636, p= 0.006). The TAF group had significantly lower levels than the ETV group: (ETV: 7.94 (0.85~179.66) vs. TAF: 4.60 (0.20~70.51); p= 0.025). The reduction in HBeAg was also greater in the TAF group: (ETV: -82.10 (-189.65, -5.99) vs. TAF: -149.77 (-267.46, -15.17); p= 0.041). At week 96, 1:2 PSM yielded 66 matched patients (ETV: 24, TAF: 42). The HBeAg clearance rate was significantly higher in the TAF group (13/42, 31.0%) than in the ETV group (2/24, 8.3%) (χ²= 4.450, p = 0.035). qHBeAg levels were significantly lower in the TAF group (2.85 (0.33~33.38)) than in the ETV group (57.35 (4.78~257.45)) (p=0.001). The TAF group also showed a greater magnitude of reduction from baseline: (ETV: -81.66 (-170.58~ -1.13) vs. TAF: -260.66 (-398.15 ~ -50.31), p&lt; 0.001). Multivariate cox analysis identified TAF treatment, baseline anti-HBe positivity , and lower baseline qHBeAg as independent predictors of HBeAg clearance.
Conclusions: For HBeAg-positive CHB patients, TAF demonstrated superior efficacy to ETV in achieving HBeAg clearance over 48-96 weeks. This effect was more pronounced in patients with lower baseline qHBeAg levels or already existing anti-HBe positivity.
DOI: 10.6084/m9.figshare.31323913.v1
title: Supplementary Material for: Comparison of HBeAg clearance rates between tenofovir alafenamide and entecavir in treatment-naive HBeAg positive chronic hepatitis B patients over 48 to 96 weeks: A retrospective cohort study

description: Objectives: This retrospective cohort study aimed to compare HBeAg clearance rates at 48 and 96 weeks in treatment-naïve, HBeAg-positive CHB patients receiving TAF versus ETV therapy 
Patients and Methods: Of 425 initially screened HBeAg-positive CHB patients, 251 were included in the 48-week analysis (ETV: 119; TAF: 132) and 101 in the 96-week analysis (ETV: 41; TAF: 60).PSM was used to balance baseline characteristics. Multivariate cox regression identified factors associated with HBeAg clearance. 
Results: At 48 weeks, a 1:1 PSM created balanced groups of 77 patients each for the 48-week comparison. the HBeAg clearance rate was significantly higher in the TAF group than in the ETV group: 22.1% versus 6.5% (χ²= 7.636, p= 0.006). The TAF group had significantly lower levels than the ETV group: (ETV: 7.94 (0.85~179.66) vs. TAF: 4.60 (0.20~70.51); p= 0.025). The reduction in HBeAg was also greater in the TAF group: (ETV: -82.10 (-189.65, -5.99) vs. TAF: -149.77 (-267.46, -15.17); p= 0.041). At week 96, 1:2 PSM yielded 66 matched patients (ETV: 24, TAF: 42). The HBeAg clearance rate was significantly higher in the TAF group (13/42, 31.0%) than in the ETV group (2/24, 8.3%) (χ²= 4.450, p = 0.035). qHBeAg levels were significantly lower in the TAF group (2.85 (0.33~33.38)) than in the ETV group (57.35 (4.78~257.45)) (p=0.001). The TAF group also showed a greater magnitude of reduction from baseline: (ETV: -81.66 (-170.58~ -1.13) vs. TAF: -260.66 (-398.15 ~ -50.31), p&lt; 0.001). Multivariate cox analysis identified TAF treatment, baseline anti-HBe positivity , and lower baseline qHBeAg as independent predictors of HBeAg clearance.
Conclusions: For HBeAg-positive CHB patients, TAF demonstrated superior efficacy to ETV in achieving HBeAg clearance over 48-96 weeks. This effect was more pronounced in patients with lower baseline qHBeAg levels or already existing anti-HBe positivity.
DOI: 10.15468/dl.5nwptv
title: Occurrence Download

description: A dataset containing 95568 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Amphibalanus",
 "HasCoordinate is true",
 "HasGeospatialIssue is false"
 ]
}

 The dataset includes 95568 records from 299 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0011128-260208012135463/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.zherxs
title: Occurrence Download

description: A dataset containing 1324 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Geometry POLYGON((122.78924 32.25571,140.33522 32.25571,140.33522 39.27110,122.78924 39.27110,122.78924 32.25571))",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 "TaxonKey is Kaloula borealis",
 "Year 2020-2025"
 ]
}

 The dataset includes 1324 records from 7 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0011191-260208012135463/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.mwm2vx
title: Occurrence Download

description: A dataset containing 243 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Abrus melanospermus melanospermus",
 "HasCoordinate is true",
 "OccurrenceStatus is Present",
 {
 "not" : {
 "BasisOfRecord" : [
 "is Fossil"
 ]
 }
 }
 ]
}

 The dataset includes 243 records from 17 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0011192-260208012135463/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.11182319
title: PanDDA analysis of SARS-CoV-2 nsp10-ExoN (space group P212121)

description: Background:

A crystallographic fragment screen against the nsp10-nsp14 ExoN heterodimeric complex was performed at the FragMAX facility (MAX IV Laboratory). Crystals were soaked with compounds from the FragMAXlib library and about half of the crystals screened belonged to space group P212121.

Description:

This repository contains a tar archive file of all files generated during the corresponding Pan-Dataset Density Analysis (PanDDA, 10.1038/ncomms15123) analysis of the respective datasets. The following PDB accession codes are associated with datasets collected during this campaign: •    9FWH (NSP1014-x0053)•    9FWJ (NSP1014-x0072)•    9FWP (NSP1014-x0109)•    9FWO (NSP1014-x0118)•    9FWQ (NSP1014-x0120)•    9FWN (NSP1014-x0121)•    9FWR (NSP1014-x0151)One dataset that had only weakly bound fragment, i.e. a fragment that could only be identified in PanDDA event maps, bit not in not be identified in 2fofc electron density and fofc difference electron density maps. This dataset were additionally analysed with the Xtrapol8 algorithm (10.1038/s42003-022-03575-7) and the full analysis was also uploaded to zenodo:•    NSP1014-x0072: 10.5281/zenodo.11182335

Reference:



Kozielski, F., Fisher, S.Z., Ma, S., Al Busaidi, F., Krupinska, E., Nyblom, M., Sele, C., Sullivan, H.M., Krojer, T., Knecht, W., 2025. Structural basis for small molecule binding to the SARS-CoV-2 nsp10–nsp14 ExoN complex. Nucleic Acids Res 53, gkaf753. https://doi.org/10.1093/nar/gkaf753
DOI: 10.5281/zenodo.11182320
title: PanDDA analysis of SARS-CoV-2 nsp10-ExoN (space group P212121)

description: Background:

A crystallographic fragment screen against the nsp10-nsp14 ExoN heterodimeric complex was performed at the FragMAX facility (MAX IV Laboratory). Crystals were soaked with compounds from the FragMAXlib library and about half of the crystals screened belonged to space group P212121.

Description:

This repository contains a tar archive file of all files generated during the corresponding Pan-Dataset Density Analysis (PanDDA, 10.1038/ncomms15123) analysis of the respective datasets. The following PDB accession codes are associated with datasets collected during this campaign: •    9FWH (NSP1014-x0053)•    9FWJ (NSP1014-x0072)•    9FWP (NSP1014-x0109)•    9FWO (NSP1014-x0118)•    9FWQ (NSP1014-x0120)•    9FWN (NSP1014-x0121)•    9FWR (NSP1014-x0151)One dataset that had only weakly bound fragment, i.e. a fragment that could only be identified in PanDDA event maps, bit not in not be identified in 2fofc electron density and fofc difference electron density maps. This dataset were additionally analysed with the Xtrapol8 algorithm (10.1038/s42003-022-03575-7) and the full analysis was also uploaded to zenodo:•    NSP1014-x0072: 10.5281/zenodo.11182335

Reference:



Kozielski, F., Fisher, S.Z., Ma, S., Al Busaidi, F., Krupinska, E., Nyblom, M., Sele, C., Sullivan, H.M., Krojer, T., Knecht, W., 2025. Structural basis for small molecule binding to the SARS-CoV-2 nsp10–nsp14 ExoN complex. Nucleic Acids Res 53, gkaf753. https://doi.org/10.1093/nar/gkaf753
DOI: 10.82261/xks3-8220
title: The Pennsylvania Sumerian Dictionary